acetic acid heptanoic acid-anhydride | 7137-28-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: acetic acid heptanoic acid-anhydride
• 英文别名: Essigsaeure-heptansaeure-anhydrid；Oenanthsaeure-essigsaeureanhydrid；Acetic heptanoic anhydride；acetyl heptanoate
• CAS: 7137-28-2
• 化学式: C₉H₁₆O₃
• 分子量: 172.224
• InChiKey: OFRQKYNQFYBASL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  乙烯酮 、 庚酸 生成 acetic acid heptanoic acid-anhydride
  参考文献：
  名称：

  Mixed Carboxylic Anhydrides in the Friedel—Crafts Reaction¹

  摘要：

  DOI：

  10.1021/jo01038a017

文献信息

• [EN] PYRANOBENZOTHIOPHENE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS<br/>[FR] DERIVES DE PYRANOBENZOTHIOPHENE DESTINES A TRAITER UNE INFECTION PAR LE VIRUS DE L'HEPATITE C
  申请人：WYETH CORP

  公开号：WO2005016932A1

  公开（公告）日：2005-02-24

  The invention is directed to a compound of the formula: (I) wherein substitutions at R1, R2 , R3 - R12, and Y are set forth in the specification; pharmaceutical compositions comprising said compound, methods of treating or preventing a Hepatitis C viral infection in a mammal comprising contacting the mammal with an effective amount of said compound or pharmaceutical compositions including said compound and methods of inhibiting replication of a Hepatitis C virus comprising contacting the HCV virus with an effective amount of said compound or pharmaceutical compositions including said compound.

  该发明涉及一种化合物，其化学式为：(I)，其中R1、R2、R3 - R12和Y的取代基在规范中说明；包括该化合物的药物组合物；用有效量的该化合物或包括该化合物的药物组合物与哺乳动物接触来治疗或预防丙型肝炎病毒感染的方法；以及用有效量的该化合物或包括该化合物的药物组合物与丙型肝炎病毒接触来抑制丙型肝炎病毒复制的方法。
• [EN] HYDROXYL-FUNCTIONALIZED PEROXIDES, THEIR PREPARATION, AND THEIR USE<br/>[FR] PEROXYDES FONCTIONNALISÉS PAR HYDROXYLE, LEUR PRÉPARATION ET LEUR UTILISATION
  申请人：AKZO NOBEL NV

  公开号：WO2010043636A1

  公开（公告）日：2010-04-22

  A hydroxyl-functionalized peroxide having the general formula (I): HO-CH2-R1-O-O-R2-CH2-OH wherein R1 and R2 are the same or different and selected from linear or branched alkyl groups containing 1-16 carbon atoms and aralkyl groups. The invention further relates to a process for preparing said hydroxyl-functionalized peroxide; the use of said peroxide as a crosslinking agent, grafting agent, curing agent, polymer degradation agent or initiator for polymerization reactions; and a process for preparing a hydroxyl-functionalized acrylic resin wherein use is made of said peroxide as an initiator.

  具有通式（I）的羟基化过氧化物：HO-CH2-R1-O-O-R2- -OH，其中R1和R2相同或不同，选择自含有1-16个碳原子的线性或支链烷基和芳基烷基。本发明还涉及制备所述羟基化过氧化物的方法；使用所述过氧化物作为交联剂、接枝剂、固化剂、聚合物降解剂或聚合反应引发剂；以及使用所述过氧化物作为引发剂制备羟基化丙烯酸树脂的方法。
• Methods and dosage forms for controlled delivery of paliperidone and risperidone
  申请人：Yam V. Nyomi

  公开号：US20050232995A1

  公开（公告）日：2005-10-20

  Dosage forms and methods for providing a substantially ascending rate of release of paliperidone or risperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone or risperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone or risperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone or risperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone or risperidone concentration that occurs following administration of paliperidone or risperidone in an immediate-release dosage form.

  本发明提供了用于提供相对升高的帕利哌酮或利培酮释放速率的剂型和方法。这种持续释放的剂型在每天一次的给药时提供治疗有效的平均稳态血浆帕利哌酮或利培酮浓度。这种一天一次的给药方案只会在每24小时内发生一次峰值血浆帕利哌酮或利培酮浓度。此外，峰值血浆帕利哌酮或利培酮浓度发生在给药后的较晚时间，并且比即时释放剂型的峰值血浆帕利哌酮或利培酮浓度具有较小的幅度。
• [EN] METHODS AND DOSAGE FORMS FOR CONTROLLED DELIVERY OF PALIPERIDONE<br/>[FR] TECHNIQUES ET FORMES DE DOSE D'APPORT COMMANDE DE PALIPERIDONE
  申请人：ALZA CORP

  公开号：WO2004010981A1

  公开（公告）日：2004-02-05

  Dosage forms and methods for providing a substantially ascending rate of release of paliperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone concentration that occurs following administration of paliperidone in an immediate-release dosage form.

  提供了用于提供相对上升速率的帕利哌酮释放的剂型和方法。持续释放的剂型在每天一次给药时提供治疗有效的平均稳态血浆帕利哌酮浓度。这种一天一次的给药方案导致每24小时期间仅出现一次峰值血浆帕利哌酮浓度。此外，峰值血浆帕利哌酮浓度发生在剂量给药后的较晚时间，并且比使用即时释放剂型的帕利哌酮给药后发生的峰值血浆帕利哌酮浓度小。
• [EN] COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER<br/>[FR] COMBINAISONS COMPRENANT DU BREXPIPRAZOLE OU UN SEL DE CELUI-CI ET UN SECOND MÉDICAMENT EN VUE D'UNE UTILISATION DANS LE TRAITEMENT D'UN TROUBLE DU SYSTÈME NERVEUX CENTRAL
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2012137971A1

  公开（公告）日：2012-10-11

  The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.

  本发明提供了一种药物，与已知的典型抗精神病药物和非典型抗精神病药物相比，具有更广泛的治疗范围，引起更少的副作用，并且在耐受性和安全性方面更为优越。本发明涉及一种药物，包含(I)化合物7-[4-(4-苯并[b]噻吩-4-基哌嗪-1-基)氧基]-1H-喹啉-2-酮或其盐，以及(II)至少一种药物，所述药物选自情绪稳定剂、血清素再摄取抑制剂、去甲肾上腺素再摄取抑制剂、血清素和去甲肾上腺素再摄取抑制剂、特异性去甲肾上腺素能抗抑郁药、抗焦虑药、三环抗抑郁药、四环抗抑郁药、抗精神病药和抗多动症药，进行组合。